Significats de arterial infusion en anglès

Ten patients with advanced gallbladder cancer were treated by arterial infusion chemotherapy.

We retrospectively studied feeding arteries and findings from 32 patients treated by arterial infusion chemotherapy.

Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients.

The feasibility of translumbar aortic placement of a port-catheter system for long-term arterial infusion was assessed.

This hepatic arterial infusion chemotherapy would be safe and feasible as therapy for inoperable intrahepatic cholangiocarcinoma.

Percutaneous placement of arterial infusion ports has been described clinically; however, existing sites of access pose unique anatomic challenges.

Methods: The treatment consisted of primary tumor resection after down-staging by local irradiation followed by hepatic arterial infusion chemotherapy.

Percutaneous hepatic arterial infusion of DDP has modest activity in the treatment of breast cancer metastatic to the liver.

RFA therapy combined with intrahepatic arterial infusion chemotherapy achieved excellent therapeutic effect, and maintained good quality of life in patients.

The present study examines the significance of defining feeding arteries to arterial infusion chemotherapy for patients with non-small cell lung carcinoma.

Systemic chemotherapy using gemcitabine is well accepted, however arterial infusion chemotherapy will be one of the options when systemic chemotherapy is fails.

We chose one method from among central venous infusion, subselective aortal infusion, selective arterial infusion, and combination of these types of infusion.

Rationale and objectives: Implantable ports for arterial infusion hold promise in a growing number of clinical applications, including regional chemotherapy and gene therapy.

Eleven of 19 patients treated with hepatic arterial infusion of 5FU had a partial response (PR).

Conclusions: Based on our results and theoretical considerations regarding hepatic arterial infusion therapy gemcitabine seems to be suitable for HAI therapy phase II studies.

Precise definition of feeding arteries and sufficient tumor staining are vital to ensure a successful outcome of arterial infusion chemotherapy for patients with NSCLC.